Novavax
NVAX
442 hedge funds and large institutions have $7.76B invested in Novavax in 2021 Q3 according to their latest regulatory filings, with 87 funds opening new positions, 172 increasing their positions, 110 reducing their positions, and 49 closing their positions.
78% more first-time investments, than exits
New positions opened: 87 | Existing positions closed: 49
56% more repeat investments, than reductions
Existing positions increased: 172 | Existing positions reduced: 110
9% more funds holding
Funds holding: 407 → 442 (+35)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
3.33% less ownership
Funds ownership: 53.66% → 50.34% (-3.3%)
8% less capital invested
Capital invested by funds: $8.42B → $7.76B (-$659M)
24% less call options, than puts
Call options by funds: $1.16B | Put options by funds: $1.53B
Top Buyers
Top Sellers
NVAX Hedge Fund Activity: Q3 2021 in Review
442 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Novavax (NVAX) for Q3 2021, worth a combined $7.76B — down 7.8% from $8.42B a quarter earlier.
Buyers outnumbered sellers: 87 funds opened new NVAX positions and 49 closed out — a net gain of 38 holders — while 172 added to existing stakes and 110 trimmed.
The largest buyer was Capital World Investors, adding an estimated $190M. The largest seller was Fidelity Investments, cutting an estimated $754M.
- 442 institutional investors held Novavax (NVAX) as of Q3 2021, up from 407 in Q2 2021.
- Funds reported $7.76B of Novavax stock for Q3 2021, down 7.8% quarter-over-quarter.
- 87 funds opened new Novavax positions in Q3 2021 and 49 closed out, a net change of +38 holders.
- The largest Novavax buyer in Q3 2021 was Capital World Investors, an estimated $190M added.
- The largest Novavax seller in Q3 2021 was Fidelity Investments, an estimated $754M sold.
Based on aggregated 13F filings for Q3 2021.